PharmaCyte Biotech Inc (PMCB) — Cash Flow Quality Index

Latest as of January 2026: -1.05x

PharmaCyte Biotech Inc (PMCB) has a Cash Flow Quality Index of -1.05x as of January 2026. Operating cash flow of $-786.85K is below net income of $746.86K, suggesting accrual-heavy earnings not yet converted to cash. Explore PharmaCyte Biotech Inc (PMCB) cash conversion ratio to assess how effectively this company generates cash.

Cash Flow Quality Index

-1.05x
Operating CF / Net Income

Operating Cash Flow

$-786.85K
USD

Net Income

$746.86K
USD

Data as of

Jan 2026
Most recent filing

PharmaCyte Biotech Inc Cash Flow Quality Index (2024–2025)

Historical Cash Flow Quality Index for PharmaCyte Biotech Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check PMCB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for PharmaCyte Biotech Inc (2024–2025)

Year-by-year earnings quality comparison for PharmaCyte Biotech Inc. For live market cap and the full company financial profile, see market value of PharmaCyte Biotech Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.10x $-2.98 Million $30.66 Million ▲ +98.5%
2024 -6.45x $-2.15 Million $333.76K
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.